CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.

Trial Details

NCT ID
NCT07538635
Phase
PHASE2
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Axicabtagene Ciloleucel
Locations (sample)
  • Hangzhou, Zhengjiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age ≥ 18 years
  • Histopathologically confirmed large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), central ne…
  • Must have received first-line treatment with a regimen containing anti-CD20 monoclonal antibody and anthracycline
  • Meet one of the following clinical high-risk factors or molecular biological high-risk factors:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →